Cannabis Stocks Falter as FDA Shares Conflicting Views on CBD After Regulatory Hearing
The fate of recent wellness rockstar, CBD—a cannabis derivative—remains unknown as the FDA debates regulation amidst growing public demand.
MORE STORIES LIKE THIS
Featured Franchise News
Featured Brand News
/story1/2710152/ac08af5307423338edf3f61ad81ca9518948.jpg)

/story1/2730467/227d535b9461bcef589dedf1f6721ed31739.jpg)
/story1/2730730/1762547985_2730730.png)
/story1/2730449/9dca5d00c32f08380879b0ba9929f98a2042.jpg)
/story1/2730975/1765487677_2730975.png)
/story1/2731051/84a667d06c0397892892a2f7c3a8d3ab227.jpg)
/story1/2730999/f7a978bbdcf0d96bc97c926690888d9f5989.jpg)
/story1/2730548/1761082102_2730548.png)
/story1/2731074/751f67f1fdc409e15ae1de962230d3498675.jpg)
/story1/2731072/5eefea341db59ca6ebac71fe719d3248253.jpg)
/story1/2731071/52e65c9477e56877c7543c52765262c27663.jpg)
/story1/2731070/714c1a0b2f19148a56292c3d08af03cb7272.jpg)